Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Feb 22, 2024
- Pharmaceuticals
- R&D
- Corporate
Eli Lilly and Company Discloses Form 10-K Including Orforglipron Related Information
| Name of listed company: | Chugai Pharmaceutical Co., Ltd. |
| Code number: | 4519 (Prime Market of Tokyo Stock Exchange) |
| Head office: | 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo |
| President & CEO: | Osamu Okuda |
| Inquiries to: | Kae Miyata |
| Head of Corporate Communications Dept. | |
| Tel:+81-(0)3-3273-0554 |
TOKYO, February 22, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Eli Lilly and Company (NYSE: LLY, Lilly) issued a Form 10-K including economic conditions of orforglipron. Orforglipron is an oral non-peptidic GLP-1 receptor agonist, created by Chugai. Lilly has the worldwide development and commercialization rights of orforglipron.
The Form 10-K includes following description:
Orforglipron
We have a license agreement with Chugai Pharmaceutical Co., Ltd (Chugai), which provides us with the worldwide development and commercialization rights to orforglipron. Chugai has the right to receive tiered royalty payments on future worldwide net sales from mid single digits to low teens if the product is successfully commercialized. As of December 31, 2023, Chugai is eligible to receive up to $140.0 million contingent upon the achievement of success-based regulatory milestones and up to $250.0 million in a series of sales-based milestones, contingent upon the commercial success of orforglipron. During the years ended December 31, 2023, 2022 and 2021, milestone payments to Chugai were not material.
Please refer to the link below for details of the Form 10-K:
Inline XBRL Viewer (sec.gov)
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp
